<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Psychopharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">JOP</journal-id><journal-title-group><journal-title>Journal of Psychopharmacology (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">0269-8811</issn><issn pub-type="epub">1461-7285</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10184186</article-id><article-id pub-id-type="pmcid-ver">PMC10184186.1</article-id><article-id pub-id-type="pmcaid">10184186</article-id><article-id pub-id-type="pmcaiid">10184186</article-id><article-id pub-id-type="pmid">37129083</article-id><article-id pub-id-type="doi">10.1177/02698811231170360</article-id><article-id pub-id-type="publisher-id">10.1177_02698811231170360</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Papers</subject></subj-group></article-categories><title-group><article-title>Effect of CannEpil<sup>&#174;</sup> on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5233-8191</contrib-id><name name-style="western"><surname>Manning</surname><given-names initials="B">Brooke</given-names></name><xref rid="aff1-02698811231170360" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4470-4718</contrib-id><name name-style="western"><surname>Hayley</surname><given-names initials="AC">Amie C</given-names></name><xref rid="aff1-02698811231170360" ref-type="aff">1</xref><xref rid="aff2-02698811231170360" ref-type="aff">2</xref><xref rid="aff3-02698811231170360" ref-type="aff">3</xref><xref rid="corresp1-02698811231170360" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Catchlove</surname><given-names initials="S">Sarah</given-names></name><xref rid="aff1-02698811231170360" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shiferaw</surname><given-names initials="B">Brook</given-names></name><xref rid="aff1-02698811231170360" ref-type="aff">1</xref><xref rid="aff4-02698811231170360" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stough</surname><given-names initials="C">Con</given-names></name><xref rid="aff1-02698811231170360" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Downey</surname><given-names initials="LA">Luke A</given-names></name><xref rid="aff1-02698811231170360" ref-type="aff">1</xref><xref rid="aff3-02698811231170360" ref-type="aff">3</xref></contrib></contrib-group><aff id="aff1-02698811231170360"><label>1</label>Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia</aff><aff id="aff2-02698811231170360"><label>2</label>International Council for Alcohol, Drugs, and Traffic Safety</aff><aff id="aff3-02698811231170360"><label>3</label>Institute for Breathing and Sleep, Austin Health, Melbourne, VIC, Australia</aff><aff id="aff4-02698811231170360"><label>4</label>Seeing Machines, Melbourne, VIC, Australia</aff><author-notes><corresp id="corresp1-02698811231170360">Amie C Hayley, Centre for Mental Health and Brain Sciences, Swinburne University of Technology, 427-451 Burwood Road, Hawthorn, VIC 3122, Australia. Email: <email>ahayley@swin.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>2</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><volume>37</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">435799</issue-id><fpage>472</fpage><lpage>483</lpage><pub-history><event event-type="pmc-release"><date><day>15</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>16</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-16 10:25:18.123"><day>16</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_02698811231170360.pdf"/><abstract><sec id="section1-02698811231170360"><title>Background:</title><p>Medicinal cannabis products containing &#916;9-tetrahydrocannabinol (THC) are increasingly accessible. Yet, policy guidelines regarding fitness to drive are lacking, and cannabinoid-specific indexations of impairment are underdeveloped.</p></sec><sec id="section2-02698811231170360"><title>Aims:</title><p>To determine the impact of a standardised 1&#8201;mL sublingual dose of CannEpil<sup>&#174;</sup>, a medicinal cannabis oil containing 100&#8201;mg cannabidiol (CBD) and 5&#8201;mg THC on simulated driving performance, relative to placebo and whether variations in vehicle control can be indexed by ocular activity.</p></sec><sec id="section3-02698811231170360"><title>Methods:</title><p>A double-blind, within-subjects, randomised, placebo-controlled, crossover trial assessed 31 healthy fully licensed drivers (15 male, 16 female) aged between 21 and 58&#8201;years (<italic toggle="yes">M</italic>&#8201;=&#8201;38.0, SD&#8201;=&#8201;10.78). Standard deviation of lateral position (SDLP), standard deviation of speed (SDS) and steering variability were assessed over time and as a function of treatment during a 40 min simulated drive, with oculomotor parameters assessed simultaneously. Oral fluid and plasma were collected at 30&#8201;min and 2.5&#8201;h.</p></sec><sec id="section4-02698811231170360"><title>Results:</title><p>CannEpil did not significantly alter SDLP across the full drive, although increased SDLP was observed between 20 and 30&#8201;min (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). CannEpil increased SDS across the full drive (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), with variance greatest at 20&#8211;30&#8201;min (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). CannEpil increased fixation duration (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), blink rate (trend <italic toggle="yes">p</italic>&#8201;=&#8201;0.051) and decreased blink duration (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) during driving. No significant correlations were observed between biological matrices and performance outcomes.</p></sec><sec id="section5-02698811231170360"><title>Conclusions:</title><p>CannEpil impairs select aspects of vehicle control (speed and weaving) over time. Alterations to ocular behaviour suggest that eye tracking may assist in determining cannabis-related driver impairment or intoxication. Australian and New Zealand Clinician Trials Registry, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://anzctr.org.au(ACTRN12619000932167)" ext-link-type="uri">https://anzctr.org.au(ACTRN12619000932167)</ext-link>.</p></sec></abstract><kwd-group><kwd>&#916;9-tetrahydrocannabinol</kwd><kwd>cannabidiol</kwd><kwd>driving performance</kwd><kwd>oculomotor</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-02698811231170360"><funding-source id="funding1-02698811231170360"><institution-wrap><institution>Cannvalate</institution><institution-id/></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section6-02698811231170360"><title>Introduction</title><p>Recent and ongoing amendments to international laws have resulted in greater access to a range of cannabis products through legalisation for recreational and therapeutic purposes (<xref rid="bibr60-02698811231170360" ref-type="bibr">Ruheel et al., 2021</xref>). Cannabidiol (CBD) and &#916;9-tetrahydrocannabinol (THC) are the two most well-known compounds found in the cannabis plant, with THC responsible for the psychoactive effects associated with cannabis use, while CBD is known for its potential therapeutic properties (<xref rid="bibr34-02698811231170360" ref-type="bibr">Kalaba and Ware, 2022</xref>). Products containing CBD and THC are increasingly utilised for their proposed medicinal properties and are commonly used in combination to manage chronic pain and conditions such as epilepsy, insomnia and anxiety (<xref rid="bibr13-02698811231170360" ref-type="bibr">Busse et al., 2021</xref>; <xref rid="bibr72-02698811231170360" ref-type="bibr">Whiting et al., 2015</xref>). Despite increased availability, there remains a lack of controlled research on their effects across a wide range of safety-critical outcomes such as driving, and methods to discern <italic toggle="yes">impairment</italic> from drug <italic toggle="yes">presence</italic> remain underdeveloped (<xref rid="bibr41-02698811231170360" ref-type="bibr">McCartney et al., 2021</xref>). In some jurisdictions, therapeutic use may result in a positive roadside saliva test for THC with potential penalties for driving under the influence, irrespective of the degree of impairment (<xref rid="bibr49-02698811231170360" ref-type="bibr">Perkins et al., 2021</xref>). Consequently, it is critical to index the specific effect of varying cannabinoid product permutations on key driving performance and visual attention outcomes.</p><p>Expert consensus shows that cannabis use is associated with at least a modest increase in crash risk (<xref rid="bibr33-02698811231170360" ref-type="bibr">International Council on Alcohol, Drugs, and Traffic Safety, 2022</xref>), and recent meta-analytic research has further revealed that drivers who test positive for THC or associated metabolites are approximately 30%&#8211;40% more likely to be involved in a collision, relative to drivers who test negative for cannabis (<xref rid="bibr57-02698811231170360" ref-type="bibr">Rogeberg et al., 2016</xref>). Acute cannabis consumption has been linked to slowed reaction time (<xref rid="bibr32-02698811231170360" ref-type="bibr">Hunault et al., 2009</xref>; <xref rid="bibr39-02698811231170360" ref-type="bibr">Liguori et al., 1998</xref>), reduced working memory capacities (<xref rid="bibr18-02698811231170360" ref-type="bibr">Curran et al., 2002</xref>; <xref rid="bibr37-02698811231170360" ref-type="bibr">Lamers et al., 2006</xref>; <xref rid="bibr50-02698811231170360" ref-type="bibr">Ploner et al., 2002</xref>; <xref rid="bibr54-02698811231170360" ref-type="bibr">Ramaekers et al., 2021</xref>; <xref rid="bibr64-02698811231170360" ref-type="bibr">Solowij et al., 2002</xref>), alertness and sustained attention abilities (<xref rid="bibr17-02698811231170360" ref-type="bibr">Crean et al., 2011</xref>; <xref rid="bibr71-02698811231170360" ref-type="bibr">Wadsworth et al., 2006</xref>), translating to a higher overall collision risk compared to unimpaired drivers (<xref rid="bibr61-02698811231170360" ref-type="bibr">Sagberg et al., 2015</xref>; <xref rid="bibr65-02698811231170360" ref-type="bibr">Tement et al., 2020</xref>). Research utilising on-road and simulated driving tasks following cannabis use has shown varying degrees of impairment on more direct measures of driving ability, including weaving of the vehicle (<xref rid="bibr25-02698811231170360" ref-type="bibr">Hartman et al., 2015</xref>; <xref rid="bibr56-02698811231170360" ref-type="bibr">Ramaekers et al., 2000</xref>), maintenance of speed (<xref rid="bibr65-02698811231170360" ref-type="bibr">Tement et al., 2020</xref>) and variability in steering (<xref rid="bibr2-02698811231170360" ref-type="bibr">Alvarez et al., 2021</xref>; <xref rid="bibr21-02698811231170360" ref-type="bibr">Downey et al., 2013</xref>; <xref rid="bibr59-02698811231170360" ref-type="bibr">Ronen et al., 2008</xref>). Impairments in driving performance associated with cannabis use are primarily attributed to THC, its main psychoactive component (<xref rid="bibr64-02698811231170360" ref-type="bibr">Solowij et al., 2002</xref>). However, extant research indicates that cannabis-induced driving impairment varies by route of administration (i.e. oral, inhaled combusted smoke, inhaled vapour), dose and sample demographics (i.e. current and past cannabis use), with such variations having important implications for current medical cannabis users. Yet, a direct causative relationship between therapeutic cannabinoid products including THC and driving behaviour is still lacking, with robust and reliable objective methods to determine driver state due to cannabis usage only in the early stages of development (e.g. <xref rid="bibr62-02698811231170360" ref-type="bibr">Shahidi Zandi et al., 2021</xref>).</p><p>Both inhaled and oral-based acute cannabis consumption has been implicated in the regulation of oculomotor processes essential to the selection and uptake of visual stimuli, with THC selectively impacting several aspects of oculomotor and visual attention processes critical to driving (<xref rid="bibr3-02698811231170360" ref-type="bibr">Arkell et al., 2022a</xref>; <xref rid="bibr50-02698811231170360" ref-type="bibr">Ploner et al., 2002</xref>). THC-associated deficits in the ability to control and suppress eye movements in a precise and deliberate manner have been shown to increase saccadic latency and inaccuracy among both acute and ongoing cannabis users (<xref rid="bibr36-02698811231170360" ref-type="bibr">Kleinloog et al., 2012</xref>; <xref rid="bibr73-02698811231170360" ref-type="bibr">Yoon et al., 2019</xref>; <xref rid="bibr74-02698811231170360" ref-type="bibr">Zuurman et al., 2008</xref>). Monitoring of ocular markers linked to driving impairment, such as saccadic activity (<xref rid="bibr19-02698811231170360" ref-type="bibr">Di Stasi et al., 2012</xref>), gaze behaviour (<xref rid="bibr35-02698811231170360" ref-type="bibr">Khan and Lee, 2019</xref>) and eyelid/blink characteristics (<xref rid="bibr20-02698811231170360" ref-type="bibr">Dong et al., 2011</xref>), has been increasingly utilised within next-generation vehicle safety systems (<xref rid="bibr29-02698811231170360" ref-type="bibr">Hayley et al., 2021</xref>). These systems presently lack sufficient specificity to distinguish cannabis use from other intoxication profiles, resulting in a critical need to index cannabinoid-specific alterations to oculomotor control to further define behavioural impairment relevant to driving (<xref rid="bibr4-02698811231170360" ref-type="bibr">Arkell et al., 2021</xref>).</p><p>A significant number of individuals who use cannabinoid preparations, particularly those containing THC, believe that their medical cannabis use does not impact their ability to drive and subsequently perceive the risks associated with driving under the influence of cannabis as relatively low (<xref rid="bibr7-02698811231170360" ref-type="bibr">Arkell et al., 2020a</xref>). According to <xref rid="bibr7-02698811231170360" ref-type="bibr">Arkell et al. (2020a)</xref>, medicinal cannabis users express a high level of confidence in their ability to accurately assess their driving performance following cannabis consumption. However, limited research exists on whether individuals&#8217; self-reported perceived driving quality reflects actual cannabis-related alterations to driving performance, particularly at lower THC dosages.</p><p>Given the multidimensional nature of driving, and the relevance of co-monitoring of ocular activity as a novel means to determine driver state due to cannabis use, the present study aims to assess whether a standard 1&#8201;mL sublingual dose of CannEpil<sup>&#174;</sup>, a 20:1 CBD to THC medicinal cannabis oil, impacts driving performance and eye-movement behaviour during driving. An absolute level of THC present in oral fluid and plasma, as well as CBD and THC metabolites 11-OH-THC and THC-COOH in plasma, were quantified following CannEpil administration to determine potential intoxication&#8211;impairment interactions. Based on the reviewed evidence, we hypothesise that the administration of CannEpil will not significantly impair driving ability, but may produce variations in eye-movement outcomes relative to placebo.</p></sec><sec sec-type="methods" id="section7-02698811231170360"><title>Methods</title><sec id="section8-02698811231170360"><title>Participants</title><p>This double-blind, within-subjects, randomised, placebo-controlled, crossover trial comprised a final sample of 31 healthy adults (16 males, 15 females) aged between 21 and 58&#8201;years old (<italic toggle="yes">M</italic>&#8201;=&#8201;38.13, SD&#8201;=&#8201;&#177;10.78) who weighed between 50 and 98&#8201;kg (<italic toggle="yes">M</italic>&#8201;=&#8201;73.10, SD&#8201;=&#8201;&#177;12.42). Recruitment was conducted via convenience sampling methods utilising print and online advertisements, and an email campaign distributed to a database of prior participants who had consented to be contacted for future studies. All participants had previous experience with cannabinoid products without any negative effects (subjective report) and were required to abstain from any illicit drug use in the 2&#8201;weeks prior to and for the duration of the study. Inclusion criteria specified that all participants are fluent in written and spoken English, have a full and unregulated driver&#8217;s licence and are all regular drivers (&gt;4000&#8201;km/year). Participants were excluded if they self-reported misuse of illicit drugs or if they had a history of substance abuse or dependence on any drugs, were taking prescription medication, had a significant medical condition, were pregnant or breastfeeding or had participated in any other investigational study within the 30&#8201;days prior to enrolment. All participants provided written informed consent. This project was approved by the Swinburne University of Technology Human Research Ethics Committee (2019/20220392-9708), and the study protocol was prospectively registered with the Australian and New Zealand Clinician Trials Registry (ACTRN12619000932167). The trial was conducted in accordance with Good Clinical Practice guidelines and the ethical standards of the Declaration of Helsinki.</p></sec><sec id="section9-02698811231170360"><title>Measures</title><sec id="section10-02698811231170360"><title>Driving simulator</title><p>Driving performance was assessed using the Forum8 driving simulator consisting of a car with adjustable seats, dashboard, steering wheel, indicators, break and accelerator pedals. Three integrated monitors were positioned in front of the steering wheel, displaying a realistic scenario and current speed. A driving simulation developed by Forum8 and tailored to Australian traffic scenarios was utilised for its previously shown sensitivity to drug and alcohol-associated driving impairment (<xref rid="bibr63-02698811231170360" ref-type="bibr">Shiferaw et al., 2019</xref>). Participants were required to drive with a steady lateral position in the left lane while maintaining a steady speed of 100&#8201;km/h for the duration of 40&#8201;min. Driving performance was assessed 90&#8201;min post-dosing. Primary outcomes were standard deviation of lateral position (SDLP), standard deviation of speed (SDS) and steering variability (SV).</p></sec><sec id="section11-02698811231170360"><title>Ocular monitoring</title><p>Oculomotor activity including gaze and blink behaviour was simultaneously recorded using a cap-mounted research-grade eye tracker by SensoMotoric Instruments (SMI, Teltow, Germany) which captures pupil and corneal reflections (with 50&#8201;Hz sampling rate) alongside a scene camera. Gaze parameters include fixation rate and duration, gaze transition entropy (GTE) and stationary gaze entropy (SGE), as outlined by <xref rid="bibr63-02698811231170360" ref-type="bibr">Shiferaw et al. (2019)</xref>. Blink parameters include rate, duration and number of microsleeps per minute. Microsleeps were defined as a blink duration of <bold>
<italic toggle="yes">&gt;</italic>
</bold>500&#8201;ms, where drivers were not otherwise engaged in a non-driving related behaviour, with this threshold previously established as significantly varied from an alert state and greater than an average event in drowsy drivers (<xref rid="bibr14-02698811231170360" ref-type="bibr">Caffier et al., 2003</xref>; <xref rid="bibr44-02698811231170360" ref-type="bibr">Mulhall et al., 2020</xref>).</p></sec><sec id="section12-02698811231170360"><title>Driving Simulator Sickness Questionnaire</title><p>Completion of driving simulations can lead to mild motion-induced sickness for some individuals. To monitor this, in combination with treatment effects, the Driving Simulator Sickness Questionnaire (DSSQ) was administered following the driving simulation task. The DSSQ is a self-report questionnaire consisting of 16 symptoms which are answered on a four-point Likert-type scale ranging from 0&#8201;=&#8201;&#8216;none&#8217; to 3&#8201;=&#8201;&#8216;severe&#8217;. Self-reports were completed during both testing visits immediately following the driving task.</p></sec><sec id="section13-02698811231170360"><title>Perceived Driving Quality Scale</title><p>Perceived driving ability was measured using the Perceived Driving Quality Scale (PDQS) developed by <xref rid="bibr69-02698811231170360" ref-type="bibr">Verster and Roth (2012)</xref>, which consists of a visual analogue scale ranging from 0&#8201;=&#8201;&#8216;I drove exceptionally poorly&#8217; to 100&#8201;=&#8201;&#8216;I drove exceptionally well&#8217;, with a midpoint of 50&#8201;=&#8201;&#8216;I drove normally&#8217;. Subjective driving assessments were collected immediately following the driving task at 135&#8201;min post-dosing.</p></sec></sec><sec id="section14-02698811231170360"><title>Acute-dosing and biological sampling procedures</title><p>The active treatment CannEpil<sup>&#174;</sup> and matched placebo were provided by MCG Pharmaceuticals. CannEpil is a phytocannabinoid-based product containing a ratio of 20:1 CBD to THC delivered in an oil vehicle and is indicated for the treatment of epilepsy and insomnia. The given dose of 1&#8201;mL CannEpil contains 100&#8201;mg of CBD and 5&#8201;mg of THC. CannEpil and placebo were centrally randomised and counterbalanced by the study sponsor (Cannvalate) with un-blinding information held by a disinterested third party (Clinical Trials Coordinator). All treatments were individually packaged and were identical in labelling, appearance and taste. At each testing session, 1&#8201;mL of palatable bearer oil containing either CannEpil or placebo was administered via a syringe sublingually. Peak effect was expected at approximately 120&#8201;min with acute effects beginning to be felt from 60&#8201;min after ingestion and potentially lasting for 4&#8211;6&#8201;h (<xref rid="bibr9-02698811231170360" ref-type="bibr">Badowski, 2017</xref>). Two experimental sessions were scheduled a minimum of 7&#8201;days apart to avoid any carryover effects.</p><p>Prior to administration of CannEpil or placebo, oral fluid was screened for the presence of THC, benzodiazepines, cocaine, amphetamines and opiates using a Securetec 6S DrugWipe to ensure drug abstinence. Oral fluid and plasma samples were collected at two time-points during each testing session, both prior to (30&#8201;min post-dosing) and following the driving task (~2.5&#8201;h post-dosing). Following collection and aliquot, oral fluid (primary and duplicate) samples were stored at &#8722;20&#176;C for shipment to Racing Analytical Services laboratory, Flemington, Victoria. All oral fluid samples were analysed in duplicate according the Australian/New Zealand Drug testing standard (AS/NZS 4308:2008). A registered research nurse collected 15&#8201;mL of venous blood via a single blood draw using an ethylenediamine tetraacetic vacutainer. Venous whole blood samples were centrifuged at 3000&#8201;rev/min for 10&#8201;min, prior to the surfaced plasma being pipetted into individual specimen vials. All collected plasma samples were stored at &#8722;80&#176;C until collection by a courier for shipment to the Victorian Institute of Forensic Medicine for biochemical analysis of THC, 11-OH-THC, THC-COOH and CBD concentrations.</p></sec><sec id="section15-02698811231170360"><title>Procedure</title><p><xref rid="fig1-02698811231170360" ref-type="fig">Figure 1</xref> displays an overview of the study schedule on testing days.</p><fig position="float" id="fig1-02698811231170360" orientation="portrait"><label>Figure 1.</label><caption><p>Overview of study session procedures.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-fig1.jpg"/></fig><p>Participants were screened over the phone prior to attending a screening visit and two experimental sessions at the Centre for Human Psychopharmacology. During screening, participants discussed their medical and drug history with a nurse, completed the Beck Depression Inventory II and Beck Anxiety Inventory (<xref rid="bibr11-02698811231170360" ref-type="bibr">Beck et al., 1961</xref>, <xref rid="bibr10-02698811231170360" ref-type="bibr">1988</xref>) for mental health screening and completed a 10 min practice session on the driving simulator. Participants were asked to have a light breakfast of something that they could replicate across both testing sessions and to abstain from alcohol for 24&#8201;h and caffeine for 12&#8201;h prior to testing sessions. Female participants were asked to provide a urine sample to test for pregnancy. Participants were informed through a departure information sheet of the potential for the study drug to remain detectable in their system for up to 48&#8201;h and of restrictions from operating a vehicle or heavy machinery after testing visits. Participants were reimbursed for their time and were provided with a transportation voucher upon leaving the testing site.</p></sec><sec id="section16-02698811231170360"><title>Statistical analyses</title><p>To account for variability in performance upon commencing the driving task, outcome data were analysed from when participants reached 90&#8201;km/h, as performed previously by <xref rid="bibr28-02698811231170360" ref-type="bibr">Hayley et al. (2018)</xref>. Driving and ocular outcomes were examined over time across four 10 min interval time-bins (T1, T2, T3 and T4) during the 40 min total drive. All statistical analyses were performed using SPSS (version 26). All analytical procedures were two-tailed, and statistical significance was defined as <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. Linear fixed effects models with restricted maximum likelihood estimation were used to investigate driving performance and oculomotor outcomes. The likelihood ratio statistic was used to determine the best-fitting variance structure with compound symmetry, or in the case of unequal variances, diagonal covariance matrices determined as best fit. For driving performance and oculomotor outcomes, both treatment condition and time were entered as repeated factors and fixed effects, with separate models built to investigate each outcome. Post hoc paired <italic toggle="yes">t</italic>-tests with planned Bonferroni adjustments for multiple comparisons were conducted to further explore differences in condition and time. Paired-samples <italic toggle="yes">t</italic>-tests were performed to investigate differences in perceived driving quality between treatment conditions. Linear regressions were used to investigate whether oral fluid and plasma THC concentrations or plasma levels of 11-THC-OH, THC-COOH and CBD were significantly correlated with driving performance or ocular outcomes.</p><p>Noting recent findings revealing sex differences in acute cannabis effects (<xref rid="bibr5-02698811231170360" ref-type="bibr">Arkell et al., 2022b</xref>), we examined covariates including sex, cannabis use history and driving experience prior to the planned analysis. Examined covariates did not significantly contribute to the explanation of results and thus were not retained in the final model. Prior to analyses, data were also evaluated for completeness, and the analysis of standard residuals was performed to identify potential outliers. Outliers were identified for outcomes including SV, blinks per minute, microsleeps, fixation duration and 30&#8201;min oral fluid THC and plasma CBD concentrations. Sensitivity analyses were conducted with and without these outliers included in the dataset, with results not altered enough for different conclusions to be drawn (i.e. no change in significance) for all outcomes. All outliers were considered genuinely unusual (i.e. not due to error) and thus were retained for analysis (<xref rid="bibr1-02698811231170360" ref-type="bibr">Aguinis et al., 2013</xref>). No other outliers were identified (Std Residual Min&#8201;=&#8201;&#8722;2.93, Std Residual Max&#8201;=&#8201;2.94).</p></sec></sec><sec sec-type="results" id="section17-02698811231170360"><title>Results</title><sec id="section18-02698811231170360"><title>Cannabis use history</title><p>Participants reported their cannabis use frequency as &#10877; once per week (9.7%), &#10877; once per fortnight (22.6%), or &#10877; once per month (16.1%). Participants who reported using cannabis more frequently than once weekly during initial screening were excluded as they did not agree to abstain from cannabis use prior to participation. The remainder of the sample (51.6%) reported having abstained from cannabis use in the 12&#8201;months prior to enrolment in the study. <xref rid="fig2-02698811231170360" ref-type="fig">Figure 2</xref> displays a Consolidated Standards of Reporting Table (CONSORT) diagram depicting recruitment flow.</p><fig position="float" id="fig2-02698811231170360" orientation="portrait"><label>Figure 2.</label><caption><p>CONSORT/flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-fig2.jpg"/></fig></sec><sec id="section19-02698811231170360"><title>Driving performance</title><p>Summary data including means and standard deviations (&#177;) for driving outcome measures are presented in <xref rid="table1-02698811231170360" ref-type="table">Table 1</xref>. There was no main effect for condition, time or its interaction for SDLP; however, post hoc analyses revealed increased SDLP in the CannEpil condition (<italic toggle="yes">M</italic>&#8201;=&#8201;28.92, SD&#8201;=&#8201;&#177;5.73) compared to placebo (<italic toggle="yes">M</italic>&#8201;=&#8201;27.08, SD&#8201;=&#8201;&#177;5.52) at T3 (<italic toggle="yes">F</italic><sub>(1,209)</sub>&#8201;=&#8201;4.60, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). There was a significant main effect for both condition (<italic toggle="yes">F</italic><sub>(1,209)</sub>&#8201;=&#8201;5.12, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) and time (<italic toggle="yes">F</italic><sub>(3,209)</sub>&#8201;=&#8201;3.67, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) for SDS, but not its interaction (<italic toggle="yes">F</italic><sub>(3,209)</sub>&#8201;=&#8201;1.16, <italic toggle="yes">p</italic>&#8201;=&#8201;0.325). Post hoc analyses revealed increased SDS in the CannEpil condition (<italic toggle="yes">M</italic>&#8201;=&#8201;2.52, SD&#8201;=&#8201;&#177;1.36) compared to placebo (<italic toggle="yes">M</italic>&#8201;=&#8201;2.01, SD&#8201;=&#8201;&#177;1.23) at T3 only (<italic toggle="yes">F</italic><sub>(1,209)</sub>&#8201;=&#8201;7.33, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). There was a main effect for time within treatment conditions for SV (<italic toggle="yes">F</italic><sub>(3,304)</sub>&#8201;=&#8201;14.73, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), with increased SV at T2 in comparison to T3 and 4 in the CannEpil condition (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). Similarly, SV was significantly increased at T2 in comparison to T1, T3 and T4, in the placebo condition (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). No other condition or interaction effect for SV was noted. Differences in driving performance outcomes SDLP, SDS and SV between CannEpil and placebo across time are displayed in <xref rid="fig3-02698811231170360" ref-type="fig">Figure 3</xref>.</p><table-wrap position="float" id="table1-02698811231170360" orientation="portrait"><label>Table 1.</label><caption><p>Driving performance (mean (SD)) overall and across time after administration of CannEpil or placebo.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="5" rowspan="1">CannEpil (<italic toggle="yes">N</italic>&#8201;=&#8201;31)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="left" rowspan="1" colspan="1">T1</th><th align="left" rowspan="1" colspan="1">T2</th><th align="left" rowspan="1" colspan="1">T3</th><th align="left" rowspan="1" colspan="1">T4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SDLP (cm)</td><td rowspan="1" colspan="1">28.07 (5.80)</td><td rowspan="1" colspan="1">27.63 (6.12)</td><td rowspan="1" colspan="1">27.91 (6.59)</td><td rowspan="1" colspan="1">28.92 (5.73)<xref rid="table-fn1-02698811231170360" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">27.82 (4.83)</td></tr><tr><td rowspan="1" colspan="1">SDS (km/h)</td><td rowspan="1" colspan="1">2.40 (1.10)<xref rid="table-fn1-02698811231170360" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">2.38 (0.83)</td><td rowspan="1" colspan="1">2.12 (1.02)</td><td rowspan="1" colspan="1">2.52 (1.36)<xref rid="table-fn2-02698811231170360" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">2.56 (1.14)</td></tr><tr><td rowspan="1" colspan="1">SV (wheel position)</td><td rowspan="1" colspan="1">&#8722;0.00002 (0.00055)</td><td rowspan="1" colspan="1">&#8722;0.00001 (0.00045)</td><td rowspan="1" colspan="1">0.00021 (0.00066)</td><td rowspan="1" colspan="1">&#8722;0.00012 (0.00067)</td><td rowspan="1" colspan="1">&#8722;0.00014 (0.00024)</td></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="5" rowspan="1">Placebo (<italic toggle="yes">N</italic>&#8201;=&#8201;31)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="left" rowspan="1" colspan="1">T1</th><th align="left" rowspan="1" colspan="1">T2</th><th align="left" rowspan="1" colspan="1">T3</th><th align="left" rowspan="1" colspan="1">T4 (N&#8201;=&#8201;30)<sup>
<xref rid="table-fn3-02698811231170360" ref-type="table-fn">a</xref>
</sup></th></tr><tr><td rowspan="1" colspan="1">SDLP (cm)</td><td rowspan="1" colspan="1">27.41 (6.20)</td><td rowspan="1" colspan="1">27.20 (6.24)</td><td rowspan="1" colspan="1">27.40 (6.73)</td><td rowspan="1" colspan="1">27.08 (5.52)</td><td rowspan="1" colspan="1">27.98 (6.53)</td></tr><tr><td rowspan="1" colspan="1">SDS (km/h)</td><td rowspan="1" colspan="1">2.19 (1.15)</td><td rowspan="1" colspan="1">2.33 (0.77)</td><td rowspan="1" colspan="1">1.98 (1.01)</td><td rowspan="1" colspan="1">2.01 (1.23)</td><td rowspan="1" colspan="1">2.42 (1.47)</td></tr><tr><td rowspan="1" colspan="1">SV (wheel position)</td><td rowspan="1" colspan="1">0.00003 (0.00039)</td><td rowspan="1" colspan="1">&#8722;0.00004 (0.0004)</td><td rowspan="1" colspan="1">0.00038 (0.00022)</td><td rowspan="1" colspan="1">&#8722;0.00007 (0.00032)</td><td rowspan="1" colspan="1">&#8722;0.00015 (0.00034)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-02698811231170360"><label>*</label><p>Indicates significantly different from placebo (<italic toggle="yes">p</italic>&#8201;&#10877;&#8201;0.05).</p></fn><fn id="table-fn2-02698811231170360"><label>**</label><p>Indicates significantly different from placebo (<italic toggle="yes">p</italic>&#8201;&#10877;&#8201;0.01).</p></fn><fn id="table-fn3-02698811231170360"><label>a</label><p>Missing data were present for a single participant during the placebo condition during T4 of the driving task.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="fig3-02698811231170360" orientation="portrait"><label>Figure 3.</label><caption><p>Variations in driving and oculomotor outcomes between CannEpil and placebo across time.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-fig3.jpg"/></fig></sec><sec id="section20-02698811231170360"><title>Oculomotor outcomes</title><p>Summary data including means and standard deviations (&#177;) for oculomotor outcomes are presented in <xref rid="table2-02698811231170360" ref-type="table">Table 2</xref>. Differences in fixation and blink duration (ms) and blink rate between CannEpil and placebo across time are displayed in <xref rid="fig3-02698811231170360" ref-type="fig">Figure 3</xref>. There was a main effect of condition for fixation duration (<italic toggle="yes">F</italic><sub>(1,91)</sub>&#8201;=&#8201;5.697, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) with significantly longer saccadic fixation in the CannEpil condition (<italic toggle="yes">M</italic>&#8201;=&#8201;714.47, SD&#8201;=&#8201;&#177;232.16) compared to placebo (<italic toggle="yes">M</italic>&#8201;=&#8201;593.06, SD&#8201;=&#8201;&#177;239.78) at T2 (<italic toggle="yes">F</italic><sub>(1,91)</sub>&#8201;=&#8201;5.461, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;.05). A significant main effect of condition for blink duration was shown (<italic toggle="yes">F</italic><sub>(1,91)</sub>&#8201;=&#8201;11.020, <italic toggle="yes">p</italic>&#8201;&#10877;&#8201;0.001), with shorter duration in the CannEpil condition (<italic toggle="yes">M</italic>&#8201;=&#8201;136.97, SD&#8201;=&#8201;&#177;38.34) relative to placebo (<italic toggle="yes">M</italic>&#8201;=&#8201;152.72, SD&#8201;=&#8201;&#177;42.87) at T4 (<italic toggle="yes">F</italic><sub>(1,91)</sub>&#8201;=&#8201;4.236, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). A trend was also observed across time for blink rate, with number of blinks per minute increasing over the duration of the drive, across both CannEpil and placebo conditions (<italic toggle="yes">F</italic><sub>(3,40)</sub>&#8201;=&#8201;2.81, <italic toggle="yes">p</italic>&#8201;=&#8201;0.051). There were no significant main effects of condition, time or their interaction for number of fixations per minute, GTE, GSE or microsleeps (all <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05).</p><table-wrap position="float" id="table2-02698811231170360" orientation="portrait"><label>Table 2.</label><caption><p>Oculomotor parameters (mean (SD)) overall and across time after administration of CannEpil or placebo.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="5" rowspan="1">CannEpil (<italic toggle="yes">N</italic>&#8201;=&#8201;14)<sup>
<xref rid="table-fn7-02698811231170360" ref-type="table-fn">a</xref>
</sup></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="left" rowspan="1" colspan="1">T1</th><th align="left" rowspan="1" colspan="1">T2</th><th align="left" rowspan="1" colspan="1">T3</th><th align="left" rowspan="1" colspan="1">T4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Fixation duration (ms)</td><td rowspan="1" colspan="1">679.12 (198.13)<xref rid="table-fn5-02698811231170360" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">703.27 (224.88)</td><td rowspan="1" colspan="1">714.47 (232.16)<xref rid="table-fn5-02698811231170360" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">668.40 (165.41)</td><td rowspan="1" colspan="1">630.36 (172.03)</td></tr><tr><td rowspan="1" colspan="1">Fixation (no.)</td><td rowspan="1" colspan="1">78.91 (15.62)</td><td rowspan="1" colspan="1">77.51 (14.97)</td><td rowspan="1" colspan="1">78.02 (17.77)</td><td rowspan="1" colspan="1">78.30 (14.56)</td><td rowspan="1" colspan="1">81.79 (16.40)</td></tr><tr><td rowspan="1" colspan="1">Blink duration (ms)</td><td rowspan="1" colspan="1">134.71 (33.66)<xref rid="table-fn6-02698811231170360" ref-type="table-fn">***</xref></td><td rowspan="1" colspan="1">130.67 (30.57)</td><td rowspan="1" colspan="1">133.21 (33.47)</td><td rowspan="1" colspan="1">138.01 (35.10)</td><td rowspan="1" colspan="1">136.97 (38.34)<xref rid="table-fn5-02698811231170360" ref-type="table-fn">*</xref></td></tr><tr><td rowspan="1" colspan="1">Blink/min (no.)</td><td rowspan="1" colspan="1">25.19 (13.06)</td><td rowspan="1" colspan="1">21.35 (11.24)</td><td rowspan="1" colspan="1">25.74 (11.40)</td><td rowspan="1" colspan="1">25.99 (10.83)</td><td rowspan="1" colspan="1">27.68 (18.01)</td></tr><tr><td rowspan="1" colspan="1">Microsleeps/min (no.)</td><td rowspan="1" colspan="1">0.50 (0.83)</td><td rowspan="1" colspan="1">0.36 (0.70)</td><td rowspan="1" colspan="1">0.31 (0.47)</td><td rowspan="1" colspan="1">0.51 (0.83)</td><td rowspan="1" colspan="1">0.82 (1.16)</td></tr><tr><td rowspan="1" colspan="1">GTE norm (bits)</td><td rowspan="1" colspan="1">0.066 (0.026)</td><td rowspan="1" colspan="1">0.064 (0.028)</td><td rowspan="1" colspan="1">0.060 (0.020)</td><td rowspan="1" colspan="1">0.070 (0.029)</td><td rowspan="1" colspan="1">0.070 (0.030)</td></tr><tr><td rowspan="1" colspan="1">SGE norm (bits)</td><td rowspan="1" colspan="1">0.372 (0.057)</td><td rowspan="1" colspan="1">0.364 (0.057)</td><td rowspan="1" colspan="1">0.364 (0.059)</td><td rowspan="1" colspan="1">0.377 (0.058)</td><td rowspan="1" colspan="1">0.384 (0.059)</td></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="5" rowspan="1">Placebo (<italic toggle="yes">N</italic>&#8201;=&#8201;14)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="left" rowspan="1" colspan="1">T1</th><th align="left" rowspan="1" colspan="1">T2</th><th align="left" rowspan="1" colspan="1">T3</th><th align="left" rowspan="1" colspan="1">T4</th></tr><tr><td rowspan="1" colspan="1">Fixation duration (ms)</td><td rowspan="1" colspan="1">617.13 (233.30)</td><td rowspan="1" colspan="1">662.01 (186.75)</td><td rowspan="1" colspan="1">593.06 (239.78)</td><td rowspan="1" colspan="1">631.66 (278.37)</td><td rowspan="1" colspan="1">581.78 (236.73)</td></tr><tr><td rowspan="1" colspan="1">Fixation (no.)</td><td rowspan="1" colspan="1">82.91 (16.80)</td><td rowspan="1" colspan="1">81.84 (14.22)</td><td rowspan="1" colspan="1">89.10 (17.90)</td><td rowspan="1" colspan="1">80.60 (16.36)</td><td rowspan="1" colspan="1">80.11 (18.63)</td></tr><tr><td rowspan="1" colspan="1">Blink duration (ms)</td><td rowspan="1" colspan="1">147.42 (37.07)</td><td rowspan="1" colspan="1">138.60 (36.99)</td><td rowspan="1" colspan="1">146.45 (35.90)</td><td rowspan="1" colspan="1">151.90 (34.41)</td><td rowspan="1" colspan="1">152.72 (42.87)</td></tr><tr><td rowspan="1" colspan="1">Blink/min (no.)</td><td rowspan="1" colspan="1">28.21 (18.72)</td><td rowspan="1" colspan="1">20.09 (10.36)</td><td rowspan="1" colspan="1">27.02 (15.80)</td><td rowspan="1" colspan="1">28.64 (16.53)</td><td rowspan="1" colspan="1">37.12 (26.36)</td></tr><tr><td rowspan="1" colspan="1">Microsleeps/min (No.)</td><td rowspan="1" colspan="1">1.09 (2.48)</td><td rowspan="1" colspan="1">0.26 (0.30)</td><td rowspan="1" colspan="1">0.40 (0.63)</td><td rowspan="1" colspan="1">1.31 (2.02)</td><td rowspan="1" colspan="1">2.39 (4.29)</td></tr><tr><td rowspan="1" colspan="1">GTE norm (bits)</td><td rowspan="1" colspan="1">0.064 (0.027)</td><td rowspan="1" colspan="1">0.059 (0.025)</td><td rowspan="1" colspan="1">0.058 (0.027)</td><td rowspan="1" colspan="1">0.069 (0.026)</td><td rowspan="1" colspan="1">0.071 (0.029)</td></tr><tr><td rowspan="1" colspan="1">SGE norm (bits)</td><td rowspan="1" colspan="1">0.369 (0.057)</td><td rowspan="1" colspan="1">0.362 (0.053)</td><td rowspan="1" colspan="1">0.360 (0.064)</td><td rowspan="1" colspan="1">0.377 (0.059)</td><td rowspan="1" colspan="1">0.376 (0.055)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn4-02698811231170360"><p>ms: milliseconds; No: number.</p></fn><fn id="table-fn5-02698811231170360"><label>*</label><p>Indicates significantly different from placebo (<italic toggle="yes">p</italic>&#8201;&#10877;&#8201;0.05).</p></fn><fn id="table-fn6-02698811231170360"><label>***</label><p>Indicates significantly different from placebo (<italic toggle="yes">p</italic>&#8201;&#10877;&#8201;0.001).</p></fn><fn id="table-fn7-02698811231170360"><label>a</label><p>Oculomotor tracking was completed for only 14 participants due to the inability to adequately calibrate the SMI eye tracker in the time permitted or participants inability to wear the cap-mounted system due to wearing eyeglasses.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section21-02698811231170360"><title>Perceived driving quality and simulator sickness</title><p>During the CannEpil condition, 39% of participants reported experiencing moderate driving simulator sickness symptom severity, compared with 27% of participants in the placebo condition. A further 6% of participants reported experiencing severe driving simulator sickness symptom severity during the CannEpil condition, including difficulty concentrating, pressure in the head and fatigue, compared with only a single participant (3%) in the placebo condition reporting severe fatigue. There were no significant differences between CannEpil (<italic toggle="yes">M</italic>&#8201;=&#8201;45.70, SD&#8201;=&#8201;&#177;26.44) and placebo (<italic toggle="yes">M</italic>&#8201;=&#8201;50.03, SD&#8201;=&#8201;&#177;16.77) in reported PDQS (<italic toggle="yes">t</italic><sub>(29)</sub>&#8201;=&#8201;1.094, <italic toggle="yes">p</italic>&#8201;=&#8201;0.283).</p></sec><sec id="section22-02698811231170360"><title>Biological sampling</title><p>Summary data including means and standard deviations for oral fluid THC levels and plasma concentrations of THC, 11-OH-THC, THC-COOH and CBD are presented in <xref rid="table3-02698811231170360" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="table3-02698811231170360" orientation="portrait"><label>Table 3.</label><caption><p>Oral fluid THC levels and plasma concentrations of THC, 11-OH-THC, THC-COOH and CBD at 30&#8201;min (T1), 2.5&#8201;h (T2) and overall.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">CannEpil T1</th><th align="left" rowspan="1" colspan="1">CannEpil T2</th><th align="left" rowspan="1" colspan="1">CannEpil overall</th><th align="left" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Oral fluid THC</td><td rowspan="1" colspan="1">576.58 (773.87)</td><td rowspan="1" colspan="1">119.04 (117.00)</td><td rowspan="1" colspan="1">347.81 (602.60)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;31</td><td rowspan="1" colspan="1">100%</td><td rowspan="1" colspan="1">94%</td><td rowspan="1" colspan="1">97%</td><td rowspan="1" colspan="1">0%</td></tr><tr><td rowspan="1" colspan="1">Plasma THC</td><td rowspan="1" colspan="1">0.043 (0.157)</td><td rowspan="1" colspan="1">0.936 (1.10)</td><td rowspan="1" colspan="1">0.489 (0.902)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;28</td><td rowspan="1" colspan="1">7%</td><td rowspan="1" colspan="1">46%</td><td rowspan="1" colspan="1">27%</td><td rowspan="1" colspan="1">0%</td></tr><tr><td rowspan="1" colspan="1">Plasma 11-OH-THC</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1.23 (2.04)</td><td rowspan="1" colspan="1">0.616 (1.56)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;28</td><td rowspan="1" colspan="1">0%</td><td rowspan="1" colspan="1">36%</td><td rowspan="1" colspan="1">18%</td><td rowspan="1" colspan="1">0%</td></tr><tr><td rowspan="1" colspan="1">Plasma THC-COOH</td><td rowspan="1" colspan="1">0.246 (0.734)</td><td rowspan="1" colspan="1">12.23 (12.83)</td><td rowspan="1" colspan="1">6.23 (10.85)</td><td rowspan="1" colspan="1">0.071 (0.264)</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;28</td><td rowspan="1" colspan="1">11%</td><td rowspan="1" colspan="1">89%</td><td rowspan="1" colspan="1">50%</td><td rowspan="1" colspan="1">7%</td></tr><tr><td rowspan="1" colspan="1">Plasma CBD</td><td rowspan="1" colspan="1">0.571 (2.19)</td><td rowspan="1" colspan="1">16.11 (19.83)</td><td rowspan="1" colspan="1">8.34 (16.03)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;28</td><td rowspan="1" colspan="1">21%</td><td rowspan="1" colspan="1">82%</td><td rowspan="1" colspan="1">52%</td><td rowspan="1" colspan="1">0%</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn8-02698811231170360"><p>Values shown are means (standard deviation) in ng/mL. Percentages shown are positive detections across the sample using a limit of detection &lt;0.5&#8201;ng/mL.</p></fn></table-wrap-foot></table-wrap><p>Concentrations of THC in oral fluid are greatest at T1 (<italic toggle="yes">M</italic>&#8201;=&#8201;576.58&#8201;ng/mL, SD&#8201;=&#8201;&#177;773.87), sampled at 30 min post-treatment consumption and significantly decline at T2 (<italic toggle="yes">M</italic>&#8201;=&#8201;119.04&#8201;ng/mL, SD&#8201;=&#8201;&#177;177), sampled at 2.5&#8201;h post-treatment consumption (<italic toggle="yes">F</italic><sub>(1,30)</sub>&#8201;=&#8201;14.51, <italic toggle="yes">p</italic>&#8201;&#10877;&#8201;0.001). Concentrations of THC, 11-OH-THC and THC-COOH in plasma are greatest at T2, sampled at ~2.5&#8201;h post-treatment consumption. Oral fluid THC concentrations and plasma levels of THC and 11-OH-THC during the placebo condition were all confirmed at 0&#8201;ng/mL. THC-COOH plasma concentrations were detected in two participants (0.9 and 1.1&#8201;ng/mL) during the placebo condition. Differences across time in oral fluid THC concentrations and levels of THC, 11-OH-THC and THC-COOH in plasma during the CannEpil condition are displayed in <xref rid="fig4-02698811231170360" ref-type="fig">Figure 4</xref>. Oral fluid THC concentrations at T1 are significantly correlated with blink rate (<italic toggle="yes">F</italic><sub>(1,12)</sub>&#8201;=&#8201;14.780, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) accounting for 55.2% of the variation of the sample, with a large size effect (adjusted <italic toggle="yes">R</italic><sup>2</sup>&#8201;=&#8201;0.515) according to <xref rid="bibr16-02698811231170360" ref-type="bibr">Cohen (1988)</xref>. Oral fluid THC concentrations correlation with blink rate is depicted in <xref rid="fig5-02698811231170360" ref-type="fig">Figure 5</xref>. No other significant correlations were observed between biological matrices and performance outcomes.</p><fig position="float" id="fig4-02698811231170360" orientation="portrait"><label>Figure 4.</label><caption><p>Means and standard deviations of oral fluid and plasma concentrations at 30&#8201;min (T1) and 2.5&#8201;h (T2) after CannEpil administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-fig4.jpg"/></fig><fig position="float" id="fig5-02698811231170360" orientation="portrait"><label>Figure 5.</label><caption><p>Oral fluid THC concentration correlation with blink rate after CannEpil administration at T1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231170360-fig5.jpg"/></fig></sec></sec><sec sec-type="discussion" id="section23-02698811231170360"><title>Discussion</title><p>This randomised, within-subjects, double-blind, placebo-controlled trial demonstrates that in healthy adults an acute sublingual dose of CannEpil<sup>&#174;</sup> impairs select aspects of vehicle control (speed and weaving) over time and alters oculomotor activity during driving relative to placebo. Increased fixation duration while monotonous highway driving under the influence of even low doses of THC may, in part, reflect time-on-task behavioural effects and increased compensatory attentional/cognitive mechanisms to counteract intoxicant sedating effects while under the influence of these substances. Standardised assessment of performance decrements at therapeutic doses will inform policy guidelines concerning responsible use of medicinal cannabis products and assist both providers and consumers in identifying potential indicators of risk during tasks such as driving.</p><p>Administration of CannEpil did not significantly alter SDLP (i.e. weaving of the vehicle) across the full length of the driving task; however, increased SDLP was observed in the CannEpil condition between 20-30&#8201;min, relative to placebo. These findings are partially consistent with previous research that links cannabis, and THC specifically, with impairments in vehicle control (<xref rid="bibr43-02698811231170360" ref-type="bibr">Moskowitz, 1985</xref>) and increased SDLP (<xref rid="bibr12-02698811231170360" ref-type="bibr">Bosker et al., 2012</xref>; <xref rid="bibr25-02698811231170360" ref-type="bibr">Hartman et al., 2015</xref>; <xref rid="bibr56-02698811231170360" ref-type="bibr">Ramaekers et al., 2000</xref>). Interestingly, <xref rid="bibr6-02698811231170360" ref-type="bibr">Arkell et al. (2019)</xref> observed that vaporisation of a combined CBD/THC preparation impaired SDLP in a more complex car following task, but not during a monotonous highway drive. Similarly, during an on-road 100&#8201;km long highway drive, a CBD-dominant vaporised cannabis preparation did not produce variations in SDLP relative to placebo, while increased SDLP was observed for THC-dominant and THC/CBD-equivalent preparations (<xref rid="bibr8-02698811231170360" ref-type="bibr">Arkell et al., 2020b</xref>). The lack of robust impairment across lateral vehicle control in the present study may be attributed to the relatively simple and monotonous driving task, which may mask the true magnitude of effects. Moreover, the high CBD to THC ratio and comparatively low THC dose of the cannabis preparation administered in the present study may have mitigated <italic toggle="yes">some</italic> of the effects of THC impairment (<xref rid="bibr22-02698811231170360" ref-type="bibr">Englund et al., 2022</xref>). It is also important to note that extant clinical research has primarily focused on smoked or vaporised cannabis, rather than sublingual or oil preparations. Given that acute intoxication may be prolonged with oral THC products (<xref rid="bibr66-02698811231170360" ref-type="bibr">Vandrey et al., 2017</xref>), differences in impairment profiles may be partially attributed to a more gradual or lesser onset of peak effects.</p><p>SDLP remains a highly sensitive index of THC-related impairment and is among the most consistently used objective measure of continuous behaviour whilst driving (<xref rid="bibr15-02698811231170360" ref-type="bibr">Charlton and Starkey, 2013</xref>; <xref rid="bibr40-02698811231170360" ref-type="bibr">Lococo and Staplin, 2006</xref>; <xref rid="bibr41-02698811231170360" ref-type="bibr">McCartney et al., 2021</xref>; <xref rid="bibr55-02698811231170360" ref-type="bibr">Ramaekers et al., 2006</xref>; <xref rid="bibr68-02698811231170360" ref-type="bibr">Verster and Roth, 2011</xref>). While SDLP may not directly predict crash risk, increases in lane weaving may predict increased lane departure occurrences (<xref rid="bibr21-02698811231170360" ref-type="bibr">Downey et al., 2013</xref>; <xref rid="bibr48-02698811231170360" ref-type="bibr">Papafotiou et al., 2005</xref>) therefore increasing the likelihood of collision (<xref rid="bibr25-02698811231170360" ref-type="bibr">Hartman et al., 2015</xref>). Many jurisdictions hold driving laws designating 0.05% or 0.08% BAC as a minimum limit of impairment, equating to a SDLP increase of approximately 2.4&#8201;cm, with this value often utilised as a comparable indicator of cannabis-related driving impairment (<xref rid="bibr25-02698811231170360" ref-type="bibr">Hartman et al., 2015</xref>; <xref rid="bibr40-02698811231170360" ref-type="bibr">Lococo and Staplin, 2006</xref>). Given the potential of greater inter-individual variability in simulated driving tasks compared to on-road tasks (<xref rid="bibr67-02698811231170360" ref-type="bibr">Veldstra et al., 2015</xref>), the observed greatest SDLP increase of 1.84&#8201;cm at only a single time point is likely not substantial enough to translate to a clinically relevant change nor of concern in the context of on-road driving.</p><p>Driving speed increased after CannEpil administration across the full length of the driving task and varied as a function of time, coinciding with increases of SDLP. Extant research has more often associated medicinal cannabis consumption with overall reductions in speed (<xref rid="bibr38-02698811231170360" ref-type="bibr">Lenn&#233; et al., 2010</xref>; <xref rid="bibr53-02698811231170360" ref-type="bibr">Rafaelsen et al., 1973</xref>; <xref rid="bibr59-02698811231170360" ref-type="bibr">Ronen et al., 2008</xref>), largely as a result of driver&#8217;s efforts to mitigate lapses in their attention (<xref rid="bibr45-02698811231170360" ref-type="bibr">Neavyn et al., 2014</xref>). Speed increases observed in the present study may reflect drivers&#8217; reduced motivations to employ compensatory driving behaviours, potentially due to an absence of task complexity or realistic driving risk associated with more simplistic simulated highway scenarios (<xref rid="bibr6-02698811231170360" ref-type="bibr">Arkell et al., 2019</xref>). The observed impairments in driving performance, which were most evident at 20&#8211;30&#8201;min, may additionally be attributed to the monotonous nature of the driving task. Participants anecdotally reported experiencing increased boredom and fatigue around this particular timeframe, providing some insight into the potential cause of the observed effects. Contrary to previous research with higher administered THC dosages (<xref rid="bibr38-02698811231170360" ref-type="bibr">Lenn&#233; et al., 2010</xref>; <xref rid="bibr58-02698811231170360" ref-type="bibr">Ronen et al., 2010</xref>), CannEpil consumption with comparatively low THC content did not alter variability in steering behaviour. Nonetheless, evidence for time-on-task effects suggests deterioration of performance during driving and some compensatory steering over-correction, which may be exacerbated during on-road conditions or during poor traffic conditions.</p><p>CannEpil increased fixation duration during driving relative to placebo, which was most pronounced between 10-20&#8201;min of the driving task. These results partially support limited previous work showing an increase in saccadic latencies following THC administration (<xref rid="bibr31-02698811231170360" ref-type="bibr">Huestegge et al., 2009</xref>; <xref rid="bibr74-02698811231170360" ref-type="bibr">Zuurman et al., 2008</xref>), particularly during immediate response tasks (<xref rid="bibr50-02698811231170360" ref-type="bibr">Ploner et al., 2002</xref>). Here, increased duration of fixation is detected between presentation of a target and commencement of the target saccade. Increased fixation duration is similarly observed among chronic ongoing cannabis users (<xref rid="bibr30-02698811231170360" ref-type="bibr">Huestegge et al., 2010</xref>) providing additional evidence implicating the cannabinergic system in temporal aspects of saccadic control during dynamic and demanding tasks such as driving.</p><p>Reductions in blink duration were additionally observed after CannEpil consumption, relative to placebo, which was most pronounced towards the final 10&#8201;min of the driving task. Decreased blink duration in the CannEpil condition coincides with the observed increase in blink rate, with less time taken to complete a blink, thereby allowing more blinks to occur. A trend was observed for number of blinks per minute across time, with blink rate gradually increasing over the duration of the drive, irrespective of treatment condition. Oral fluid THC concentrations at 30&#8201;min also showed a strong positive relationship with blink rate, suggesting a potentially shared mechanism in acute-dosing conditions. Decreased blink duration following CannEpil consumption may be linked to increased occurrences of cannabis-induced eyelid tremors (<xref rid="bibr27-02698811231170360" ref-type="bibr">Hartman et al., 2016</xref>; <xref rid="bibr51-02698811231170360" ref-type="bibr">Porath and Beirness, 2019</xref>; <xref rid="bibr52-02698811231170360" ref-type="bibr">Porath-Waller and Beirness, 2013</xref>) or increased ocular irritation given the proposed involvement of cannabinoid receptors in the modulation of ocular pain and inflammation that can trigger dry eye (<xref rid="bibr46-02698811231170360" ref-type="bibr">Nguyen and Wu, 2019</xref>; <xref rid="bibr70-02698811231170360" ref-type="bibr">Vu&#269;kovi&#263; et al., 2018</xref>). While blink rate may provide a useful indicator for recency of use, its contribution to predicting behavioural effects relevant to traffic safety are likely peripheral at best. Developments in objective impairment monitoring utilising eye-movement behaviour may help advance methods to determine driver impairment or intoxication due to cannabis consumption, particularly following recent/acute use.</p><p>THC concentrations in oral fluid were not significantly correlated with driving performance outcomes or oculomotor outcomes revealing of functional impairment. This finding is supported by extant research demonstrating that THC in oral fluid is generally detectable in its highest concentration immediately after cannabis consumption (<xref rid="bibr66-02698811231170360" ref-type="bibr">Vandrey et al., 2017</xref>), but highlights the inter and intra-individual variability in THC elimination over time (<xref rid="bibr47-02698811231170360" ref-type="bibr">Niedbala et al., 2001</xref>). Thus, it is likely a relatively poor indicator of cannabis/THC induced impairment (<xref rid="bibr42-02698811231170360" ref-type="bibr">McCartney et al., 2022</xref>). Plasma concentrations of THC, 11-OH-THC, THC-COOH and CBD were also not significantly correlated with driving or ocular outcomes, underscoring the weak association between detected levels of THC or its metabolites and behavioural effects, particularly at lower THC dosages (<xref rid="bibr24-02698811231170360" ref-type="bibr">Ginsburg, 2019</xref>). Despite this, the presence of THC in oral fluid concentrations during the present study may produce a positive result for THC on roadside saliva drug tests within 2&#8201;h of using this treatment, potentially exposing drivers to legal penalties despite a lack of objective behavioural impairment.</p><sec id="section24-02698811231170360"><title>Limitations and future research</title><p>The findings from the present study are to be considered in light of some methodological limitations. As the study was limited to healthy volunteers who were primarily non-regular users of cannabis, our ability to generalise these results to those who consume medicinal cannabis products at higher doses or frequency is not clearly established. As CannEpil was administered as a single acute dose in the present study, the potential impact of repeated dosages also remains unclear. Indeed, more regular cannabis use may facilitate partial tolerance to the effects of CBD and/or THC (<xref rid="bibr8-02698811231170360" ref-type="bibr">Arkell et al., 2020b</xref>; <xref rid="bibr26-02698811231170360" ref-type="bibr">Hartman and Huestis, 2013</xref>) and further diminish observable driving performance impairments such as those reported in the present study. Secondly, the use of a simulated driving task involving a simplistic highway drive with less traffic and perceptual cues than would be typically encountered during on-road scenarios may protect against sensitivity to THC&#8217;s impairing effects that are associated with greater neurocognitive demand (<xref rid="bibr26-02698811231170360" ref-type="bibr">Hartman and Huestis, 2013</xref>). While this type of highway driving task has previously shown sensitivity to drug and alcohol-related impairment, it is likely that the intricacies of real-world driving are still not fully represented. Despite this, simulated driving tasks remain essential in providing objective and accurate representations of driving ability in a time-sensitive manner.</p><p>We acknowledge that our study did not gather information on abuse liability, as we utilised an acute-dosing paradigm. Although we recognise that subjective intoxicant effects are an important consideration, we did not include these measures in the present work, and this is a noteworthy limitation. Lastly, oculomotor results were not available for the entire sample, due to technical issues with device calibration. To preserve overall data integrity, some cases were discarded for our analysis (e.g. where only one of two ocular measures was captured). Nonetheless, this is the largest and most robust acute-dosing paradigm which examines ocular behaviour during driving under the influence of a representative cannabis medication in applied settings to date, and thus overcomes much of the issues with previous work in this emerging space (<xref rid="bibr23-02698811231170360" ref-type="bibr">Fant et al., 1997</xref>; <xref rid="bibr50-02698811231170360" ref-type="bibr">Ploner et al., 2002</xref>; <xref rid="bibr62-02698811231170360" ref-type="bibr">Shahidi Zandi et al., 2021</xref>).</p><p>Future research is encouraged to evaluate the impact of repeated doses over extended periods of time, to assess whether observed behavioural changes are mitigated or altered by partial tolerance effects. In addition, incorporating measures to assess the impact of subjective intoxication on performance would provide valuable insight. Future research would further benefit from inclusion of diverse groups of medical cannabis consuming patient populations to expand our understanding of how ocular parameters may be altered during driving tasks, and whether this is contingent on experience, setting or treatment modality. This will serve to better distinguish the extent to which specific performance domains are sensitive to cannabis-related impairment and under what degree of task demand such impairment arises.</p></sec></sec><sec sec-type="conclusions" id="section25-02698811231170360"><title>Conclusion</title><p>An acute dose of CannEpil produces objective impairment in vehicle control characterised by deficits in maintenance of vehicle speed, and to a lesser extent, maintenance of lateral positioning. Concurrent increases in fixation duration and reductions in blink duration after cannabis consumption provide additional evidence for the role of cannabis in the regulation of oculomotor control and provide possible points for objective intoxication monitoring. Biological sampling data suggest that cannabinoid and metabolite concentrations in oral fluid and plasma are not highly indicative of impairment nor reflect key performance indicators.</p></sec><sec sec-type="supplementary-material" id="section26-02698811231170360" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-02698811231170360" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-jop-10.1177_02698811231170360 &#8211; Supplemental material for Effect of CannEpil&#174; on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-jop-10.1177_02698811231170360.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, sj-docx-1-jop-10.1177_02698811231170360 for Effect of CannEpil&#174; on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial by Brooke Manning, Amie C Hayley, Sarah Catchlove, Brook Shiferaw, Con Stough and Luke A Downey in Journal of Psychopharmacology</p></supplementary-material></sec></body><back><fn-group><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ACH is supported by a Rebecca L. Cooper Al and Val Rosenstrauss Fellowship (GNT: F2021894). All other authors declare that there is no conflict of interest.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research project findings discussed here were supported by a research grant from Cannvalate (Australia), Toorak, Australia to the Principal Investigator and study author, Prof. Luke Downey. The authors confirm that the study sponsor did not have any influence on the decision to publish the manuscript nor the information contained within.</p></fn><fn fn-type="other"><p><bold>ORCID iDs:</bold> Brooke Manning <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_02698811231170360-img1.jpg"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-5233-8191" ext-link-type="uri">https://orcid.org/0000-0001-5233-8191</ext-link></p><p>Amie C Hayley <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_02698811231170360-img1.jpg"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-4470-4718" ext-link-type="uri">https://orcid.org/0000-0002-4470-4718</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguinis</surname><given-names>H</given-names></name><name name-style="western"><surname>Gottfredson</surname><given-names>RK</given-names></name><name name-style="western"><surname>Joo</surname><given-names>H</given-names></name></person-group> (<year>2013</year>) <article-title>Best-practice recommendations for defining, identifying, and handling outliers</article-title>. <source>Organ Res Methods</source><volume>16</volume>: <fpage>270</fpage>&#8211;<lpage>301</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/1094428112470848</pub-id></mixed-citation></ref><ref id="bibr2-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>L</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Young and under the influence: A systematic review of the impact of cannabis on the driving performance of youth</article-title>. <source>Accid Anal Prev</source><volume>151</volume>: <fpage>105961</fpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2020.105961</pub-id><pub-id pub-id-type="pmid">33421731</pub-id></mixed-citation></ref><ref id="bibr3-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Brooks-Russell</surname><given-names>A</given-names></name><name name-style="western"><surname>Downey</surname><given-names>LA</given-names></name></person-group>, <etal>et al</etal>. (<year>2022</year>a) <article-title>Effects of psychotropic drugs on ocular parameters relevant to traffic safety: A systematic review</article-title>. <source>Neurosci Biobehav Rev</source><volume>141</volume>: <fpage>104831</fpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neubiorev.2022.104831</pub-id><pub-id pub-id-type="pmid">35995080</pub-id><pub-id pub-id-type="pmcid">PMC10067018</pub-id></mixed-citation></ref><ref id="bibr4-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Hayley</surname><given-names>AC</given-names></name><name name-style="western"><surname>Downey</surname><given-names>LA</given-names></name></person-group> (<year>2021</year>) <article-title>Managing the high: Developing legislation and detection methods for cannabis impairment</article-title>. <source>Nat Rev Neurosci</source><volume>22</volume>: <fpage>584</fpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41583-021-00500-5.</pub-id><pub-id pub-id-type="pmid">34285406</pub-id></mixed-citation></ref><ref id="bibr5-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Kevin</surname><given-names>RC</given-names></name><name name-style="western"><surname>Vinckenbosch</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>. (<year>2022</year>b) <article-title>Sex differences in acute cannabis effects revisited: Results from two randomized controlled trials</article-title>. <source>Addict Biol</source><volume>27</volume>: e13125. DOI: <pub-id pub-id-type="doi">10.1111/adb.13125</pub-id><pub-id pub-id-type="pmcid">PMC9286641</pub-id><pub-id pub-id-type="pmid">34936167</pub-id></mixed-citation></ref><ref id="bibr6-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></name><name name-style="western"><surname>Kevin</surname><given-names>RC</given-names></name></person-group>, <etal>et al</etal>. (<year>2019</year>) <article-title>Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition</article-title>. <source>Psychopharmacology</source><volume>236</volume>: <fpage>2713</fpage>&#8211;<lpage>2724</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-019-05246-8.</pub-id><pub-id pub-id-type="pmid">31044290</pub-id><pub-id pub-id-type="pmcid">PMC6695367</pub-id></mixed-citation></ref><ref id="bibr7-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></name><name name-style="western"><surname>Mills</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. (<year>2020</year>a) <article-title>Driving-related behaviours, attitudes, and perceptions among Australian medicinal cannabis users: Results from the CAMS 18-19 survey</article-title>. <source>Accid Anal Prev</source><volume>148</volume>: <fpage>105784</fpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2020.105784</pub-id><pub-id pub-id-type="pmid">33017729</pub-id></mixed-citation></ref><ref id="bibr8-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Vinckenbosch</surname><given-names>F</given-names></name><name name-style="western"><surname>Kevin</surname><given-names>RC</given-names></name></person-group>, <etal>et al</etal>. (<year>2020</year>b) <article-title>Effect of cannabidiol and &#916;9-tetrahydrocannabinol on driving performance: A randomised clinical trial</article-title>. <source>JAMA</source>, <volume>324</volume>(<issue>21</issue>), <fpage>2177</fpage>&#8211;<lpage>2186</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.2020.21218.</pub-id><pub-id pub-id-type="pmid">33258890</pub-id><pub-id pub-id-type="pmcid">PMC7709000</pub-id></mixed-citation></ref><ref id="bibr9-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badowski</surname><given-names>ME</given-names></name></person-group> (<year>2017</year>) <article-title>A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: A focus on pharmacokinetic variability and pharmacodynamics</article-title>. <source>Cancer Chemother Pharmacol</source><volume>80</volume>: <fpage>441</fpage>&#8211;<lpage>449</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00280-017-3387-5.</pub-id><pub-id pub-id-type="pmid">28780725</pub-id><pub-id pub-id-type="pmcid">PMC5573753</pub-id></mixed-citation></ref><ref id="bibr10-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>AT</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>N</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. (<year>1988</year>) <article-title>An inventory for measuring clinical anxiety: Psychometric properties</article-title>. <source>J Consult Clin Psychol</source><volume>56</volume>: <fpage>893</fpage>. DOI: <pub-id pub-id-type="doi">10.1037//0022-006x.56.6.893.</pub-id><pub-id pub-id-type="pmid">3204199</pub-id></mixed-citation></ref><ref id="bibr11-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>AT</given-names></name><name name-style="western"><surname>Ward</surname><given-names>CH</given-names></name><name name-style="western"><surname>Mendelson</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. (<year>1961</year>) <article-title>An inventory for measuring depression</article-title>. <source>Arch Gen Psychiatry</source><volume>4</volume>: <fpage>561</fpage>&#8211;<lpage>571</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/archpsyc.1961.01710120031004.</pub-id><pub-id pub-id-type="pmid">13688369</pub-id></mixed-citation></ref><ref id="bibr12-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosker</surname><given-names>WM</given-names></name><name name-style="western"><surname>Theunissen</surname><given-names>EL</given-names></name><name name-style="western"><surname>Conen</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>A placebo-controlled study to assess standardized field sobriety tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid</article-title>. <source>Psychopharmacology</source><volume>223</volume>: <fpage>439</fpage>&#8211;<lpage>446</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-012-2732-y.</pub-id><pub-id pub-id-type="pmid">22581391</pub-id><pub-id pub-id-type="pmcid">PMC3456923</pub-id></mixed-citation></ref><ref id="bibr13-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busse</surname><given-names>JW</given-names></name><name name-style="western"><surname>Vankrunkelsven</surname><given-names>P</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Medical cannabis or cannabinoids for chronic pain: A clinical practice guideline</article-title>. <source>BMJ</source><volume>374</volume>: n2040. DOI: <pub-id pub-id-type="doi">10.1136/bmj.n2040.</pub-id><pub-id pub-id-type="pmid">34497062</pub-id></mixed-citation></ref><ref id="bibr14-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caffier</surname><given-names>PP</given-names></name><name name-style="western"><surname>Erdmann</surname><given-names>U</given-names></name><name name-style="western"><surname>Ullsperger</surname><given-names>P</given-names></name></person-group> (<year>2003</year>) <article-title>Experimental evaluation of eye-blink parameters as a drowsiness measure</article-title>. <source>Eur J Appl Physiol</source><volume>89</volume>: <fpage>319</fpage>&#8211;<lpage>325</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.sleep.2004.11.013.</pub-id><pub-id pub-id-type="pmid">12736840</pub-id></mixed-citation></ref><ref id="bibr15-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charlton</surname><given-names>SG</given-names></name><name name-style="western"><surname>Starkey</surname><given-names>NJ</given-names></name></person-group> (<year>2013</year>) <article-title>Driving on familiar roads: Automaticity and inattention blindness</article-title>. <source>Transp Res Part F</source><volume>19</volume>: <fpage>121</fpage>&#8211;<lpage>133</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.trf.2013.03.008.</pub-id></mixed-citation></ref><ref id="bibr16-02698811231170360"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name></person-group> (<year>1988</year>) <source>Statistical Power Analysis for the Behavioral Sciences</source>, <edition>2nd edn.</edition><publisher-loc>New York, NY</publisher-loc>: <publisher-name>Routledge</publisher-name>.</mixed-citation></ref><ref id="bibr17-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crean</surname><given-names>RD</given-names></name><name name-style="western"><surname>Crane</surname><given-names>NA</given-names></name><name name-style="western"><surname>Mason</surname><given-names>BJ</given-names></name></person-group> (<year>2011</year>) <article-title>An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions</article-title>. <source>J Addict Med</source><volume>5</volume>: <fpage>1</fpage>&#8211;<lpage>8</lpage>. DOI: <pub-id pub-id-type="doi">10.1097/ADM.0b013e31820c23fa.</pub-id><pub-id pub-id-type="pmid">21321675</pub-id><pub-id pub-id-type="pmcid">PMC3037578</pub-id></mixed-citation></ref><ref id="bibr18-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curran</surname><given-names>VH</given-names></name><name name-style="western"><surname>Brignell</surname><given-names>C</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2002</year>) <article-title>Cognitive and subjective dose-response effects of acute oral &#916;9-tetrahydrocannabinol (THC) in infrequent cannabis users</article-title>. <source>Psychopharmacology</source>, <volume>164</volume>: <fpage>61</fpage>&#8211;<lpage>70</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-002-1169-0.</pub-id><pub-id pub-id-type="pmid">12373420</pub-id></mixed-citation></ref><ref id="bibr19-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Stasi</surname><given-names>LL</given-names></name><name name-style="western"><surname>Renner</surname><given-names>R</given-names></name><name name-style="western"><surname>Catena</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>Towards a driver fatigue test based on the saccadic main sequence: A partial validation by subjective report data</article-title>. <source>Transp Res Part C: Emerg Technols</source><volume>21</volume>: <fpage>122</fpage>&#8211;<lpage>133</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.trc.2011.07.002.</pub-id></mixed-citation></ref><ref id="bibr20-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Uchimura</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. (<year>2011</year>) <article-title>Driver inattention monitoring system for intelligent vehicles: A review</article-title>. <source>IEEE Trans Intell Transp Syst</source><volume>12</volume>: <fpage>596</fpage>&#8211;<lpage>614</lpage>. DOI: <pub-id pub-id-type="doi">10.1109/TITS.2010.2092770.</pub-id></mixed-citation></ref><ref id="bibr21-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Downey</surname><given-names>LA</given-names></name><name name-style="western"><surname>King</surname><given-names>R</given-names></name><name name-style="western"><surname>Papafotiou</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. (<year>2013</year>) <article-title>The effects of cannabis and alcohol on simulated driving: Influences of dose and experience</article-title>. <source>Accid Anal Prev</source><volume>50</volume>: <fpage>879</fpage>&#8211;<lpage>886</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2012.07.016.</pub-id><pub-id pub-id-type="pmid">22871272</pub-id></mixed-citation></ref><ref id="bibr22-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Englund</surname><given-names>A</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>D</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. (<year>2022</year>) <article-title>Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD: THC ratios</article-title>. <source>Neuropsychopharmacology</source>. Epub ahead of print 16 November 2022. DOI: <pub-id pub-id-type="doi">10.1038/s41386-022-01478-z.</pub-id><pub-id pub-id-type="pmcid">PMC10156730</pub-id><pub-id pub-id-type="pmid">36380220</pub-id></mixed-citation></ref><ref id="bibr23-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fant</surname><given-names>RV</given-names></name><name name-style="western"><surname>Heishman</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bunker</surname><given-names>EB</given-names></name></person-group>, <etal>et al</etal>. (<year>1997</year>) <article-title>Acute and residual effects of marijuana in humans</article-title>. <source>Pharmacol Biochem Behav</source><volume>60</volume>: <fpage>777</fpage>&#8211;<lpage>784</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/S0091-3057(97)00386-9.</pub-id><pub-id pub-id-type="pmid">9700958</pub-id></mixed-citation></ref><ref id="bibr24-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginsburg</surname><given-names>BC</given-names></name></person-group> (<year>2019</year>) <article-title>Strengths and limitations of two cannabis-impaired driving detection methods: A review of the literature</article-title>. <source>Am J Drug Alcohol Abuse</source><volume>45</volume>: <fpage>610</fpage>&#8211;<lpage>622</lpage>. DOI: <pub-id pub-id-type="doi">10.1080/00952990.2019.1655568.</pub-id><pub-id pub-id-type="pmid">31498702</pub-id></mixed-citation></ref><ref id="bibr25-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Brown</surname><given-names>TL</given-names></name><name name-style="western"><surname>Milavetz</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. (<year>2015</year>) <article-title>Cannabis effects on driving lateral control with and without alcohol</article-title>. <source>Drug Alcohol Depend</source><volume>154</volume>: <fpage>25</fpage>&#8211;<lpage>37</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.06.015</pub-id><pub-id pub-id-type="pmid">26144593</pub-id><pub-id pub-id-type="pmcid">PMC4536116</pub-id></mixed-citation></ref><ref id="bibr26-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Huestis</surname><given-names>MA</given-names></name></person-group> (<year>2013</year>) <article-title>Cannabis effects of driving skills</article-title>. <source>Clin Chem</source><volume>59</volume>: <fpage>478</fpage>&#8211;<lpage>492</lpage>. DOI: <pub-id pub-id-type="doi">10.1373/clinchem.2012.194381.</pub-id><pub-id pub-id-type="pmid">23220273</pub-id><pub-id pub-id-type="pmcid">PMC3836260</pub-id></mixed-citation></ref><ref id="bibr27-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Richman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>CE</given-names></name></person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Drug recognition expert (DRE) examination characteristics of cannabis impairment</article-title>. <source>Accid Anal Prev</source><volume>92</volume>: <fpage>219</fpage>&#8211;<lpage>229</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2016.04.012</pub-id><pub-id pub-id-type="pmid">27107471</pub-id></mixed-citation></ref><ref id="bibr28-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayley</surname><given-names>AC</given-names></name><name name-style="western"><surname>Green</surname><given-names>M</given-names></name><name name-style="western"><surname>Downey</surname><given-names>LA</given-names></name></person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>The acute and residual effects of escalating, analgesic-range doses of ketamine of driving performance: A simulator study</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source><volume>86</volume>: <fpage>83</fpage>&#8211;<lpage>88</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.pnpbp.2018.05.015.</pub-id><pub-id pub-id-type="pmid">29782960</pub-id></mixed-citation></ref><ref id="bibr29-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayley</surname><given-names>AC</given-names></name><name name-style="western"><surname>Shiferaw</surname><given-names>B</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Driver monitoring systems (DMS): The future of impaired driving management?</article-title><source>Traffic Inj Prev</source><volume>22</volume>: <fpage>313</fpage>&#8211;<lpage>317</lpage>. DOI: <pub-id pub-id-type="doi">10.1080/15389588.2021.1899164</pub-id><pub-id pub-id-type="pmid">33829941</pub-id></mixed-citation></ref><ref id="bibr30-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huestegge</surname><given-names>L</given-names></name><name name-style="western"><surname>Kunert</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Radach</surname><given-names>R</given-names></name></person-group> (<year>2010</year>) <article-title>Long-term effects of cannabis on eye movement control in reading</article-title>. <source>Psychopharmacology</source><volume>209</volume>: <fpage>77</fpage>&#8211;<lpage>84</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-009-1769-z.</pub-id><pub-id pub-id-type="pmid">20091152</pub-id></mixed-citation></ref><ref id="bibr31-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huestegge</surname><given-names>L</given-names></name><name name-style="western"><surname>Radach</surname><given-names>R</given-names></name><name name-style="western"><surname>Kunert</surname><given-names>H</given-names></name></person-group> (<year>2009</year>) <article-title>Long-term effects of cannabis on oculomotor function in humans</article-title>. <source>J Psychopharmacol</source><volume>23</volume>: <fpage>714</fpage>&#8211;<lpage>722</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881108091601.</pub-id><pub-id pub-id-type="pmid">18562415</pub-id></mixed-citation></ref><ref id="bibr32-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunault</surname><given-names>CC</given-names></name><name name-style="western"><surname>Mensinga</surname><given-names>TT</given-names></name><name name-style="western"><surname>B&#246;cker</surname><given-names>KBE</given-names></name></person-group>, <etal>et al</etal>. (<year>2009</year>) <article-title>Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC)</article-title>. <source>Psychopharmacology</source><volume>204</volume>: <fpage>85</fpage>&#8211;<lpage>94</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-008-1440-0</pub-id><pub-id pub-id-type="pmid">19099294</pub-id></mixed-citation></ref><ref id="bibr33-02698811231170360"><mixed-citation publication-type="webpage"><collab>International Council on Alcohol, Drugs, &amp; Traffic Safety</collab> (<year>2022</year>) <source>Cannabis &amp; Driving Fact Sheet 3: Recent Epidemiological Evidence</source>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.icadtsinternational.com/resources/Documents/Fact%20Sheets/ICADTS-Cannabis-Recent%20Epidemiological%20Evidence-19.pdf" ext-link-type="uri">https://www.icadtsinternational.com/resources/Documents/Fact%20Sheets/ICADTS-Cannabis-Recent%20Epidemiological%20Evidence-19.pdf</ext-link> (<comment>accessed 12 October 2022</comment>).</mixed-citation></ref><ref id="bibr34-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalaba</surname><given-names>M</given-names></name><name name-style="western"><surname>Ware</surname><given-names>MA</given-names></name></person-group> (<year>2022</year>) <article-title>Cannabinoid profiles in medical cannabis users: Effects of age, gender, symptoms, and duration of use</article-title>. <source>Cannabis Cannabinoid Res</source><volume>7</volume>: <fpage>840</fpage>&#8211;<lpage>851</lpage>. DOI: <pub-id pub-id-type="doi">10.1089/can.2020.0120.</pub-id><pub-id pub-id-type="pmid">33999649</pub-id><pub-id pub-id-type="pmcid">PMC9784598</pub-id></mixed-citation></ref><ref id="bibr35-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>MQ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name></person-group> (<year>2019</year>) <article-title>Gaze and eye tracking: Techniques and applications in ADAS</article-title>. <source>Sensors</source><volume>19</volume>: <fpage>5540</fpage>. DOI: <pub-id pub-id-type="doi">10.3390/s19245540.</pub-id><pub-id pub-id-type="pmid">31847432</pub-id><pub-id pub-id-type="pmcid">PMC6960643</pub-id></mixed-citation></ref><ref id="bibr36-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinloog</surname><given-names>D</given-names></name><name name-style="western"><surname>Liem-Moolenaar</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>Does olanzapine inhibit the psychomimetic effects of delta-9-tetrahydrocannabinol?</article-title><source>J Psychopharmacol</source><volume>26</volume>: <fpage>1307</fpage>&#8211;<lpage>1316</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881112446534.</pub-id><pub-id pub-id-type="pmid">22596206</pub-id></mixed-citation></ref><ref id="bibr37-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamers</surname><given-names>CTJ</given-names></name><name name-style="western"><surname>Bechara</surname><given-names>A</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. (<year>2006</year>) <article-title>Cognitive function and mood in MDMA/THC users, THC users, and non-drug using controls</article-title>. <source>J Psychopharmacol</source><volume>20</volume>: <fpage>302</fpage>&#8211;<lpage>311</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881106059495</pub-id><pub-id pub-id-type="pmid">16510488</pub-id></mixed-citation></ref><ref id="bibr38-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenn&#233;</surname><given-names>MG</given-names></name><name name-style="western"><surname>Dietze</surname><given-names>PM</given-names></name><name name-style="western"><surname>Triggs</surname><given-names>TJ</given-names></name></person-group>, <etal>et al</etal>. (<year>2010</year>) <article-title>The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand</article-title>. <source>Accid Anal Prev</source><volume>42</volume>: <fpage>859</fpage>&#8211;<lpage>866</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2009.04.021.</pub-id><pub-id pub-id-type="pmid">20380913</pub-id></mixed-citation></ref><ref id="bibr39-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liguori</surname><given-names>A</given-names></name><name name-style="western"><surname>Gatto</surname><given-names>CP</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J</given-names></name></person-group> (<year>1998</year>) <article-title>Effects of marijuana on equilibrium, psychomotor performance, and simulated driving</article-title>. <source>Behav Pharmacol</source><volume>9</volume>: <fpage>599</fpage>&#8211;<lpage>609</lpage>. DOI: <pub-id pub-id-type="doi">10.1097/00008877-199811000-00015</pub-id><pub-id pub-id-type="pmid">9862085</pub-id></mixed-citation></ref><ref id="bibr40-02698811231170360"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lococo</surname><given-names>KH</given-names></name><name name-style="western"><surname>Staplin</surname><given-names>L</given-names></name></person-group> (<year>2006</year>) <source>Literature review of polypharmacy and older drivers: Identifying strategies to collect drug usage and driving functioning among older drivers</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Highway Traffic Safety Administration, US Department of Transportation</publisher-name>. DOI: <pub-id pub-id-type="doi">10.1037/e729542011-001</pub-id></mixed-citation></ref><ref id="bibr41-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCartney</surname><given-names>D</given-names></name><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Irwin</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Determining the magnitude and duration of acute &#916;9-tetrahydrocannabinol (&#916;9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review</article-title>. <source>Neurosci Biobehav Rev</source><volume>126</volume>: <fpage>175</fpage>&#8211;<lpage>193</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.02.003.</pub-id><pub-id pub-id-type="pmid">33497784</pub-id></mixed-citation></ref><ref id="bibr42-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCartney</surname><given-names>D</given-names></name><name name-style="western"><surname>Arkell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Irwin</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. (<year>2022</year>) <article-title>Are blood and oral fluid &#916;9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis</article-title>. <source>Neurosci Biobehav Rev</source><volume>134</volume>: <fpage>104433</fpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.11.004</pub-id><pub-id pub-id-type="pmid">34767878</pub-id></mixed-citation></ref><ref id="bibr43-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moskowitz</surname><given-names>H</given-names></name></person-group> (<year>1985</year>) <article-title>Marihuana and driving</article-title>. <source>Accid Anal Prev</source><volume>17</volume>: <fpage>323</fpage>&#8211;<lpage>345</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/0001-4575(85)90034-X.</pub-id><pub-id pub-id-type="pmid">3006718</pub-id></mixed-citation></ref><ref id="bibr44-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulhall</surname><given-names>MD</given-names></name><name name-style="western"><surname>Cori</surname><given-names>J</given-names></name><name name-style="western"><surname>Sletten</surname><given-names>TL</given-names></name></person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>A pre-drive ocular assessment predicts alertness and driving impairment: A naturalistic driving study in shift workers</article-title>. <source>Accid Anal Prev</source><volume>135</volume>: <fpage>105386</fpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2019.105386</pub-id><pub-id pub-id-type="pmid">31805427</pub-id></mixed-citation></ref><ref id="bibr45-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neavyn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Blohm</surname><given-names>E</given-names></name><name name-style="western"><surname>Babu</surname><given-names>KM</given-names></name></person-group>, <etal>et al</etal>. (<year>2014</year>) <article-title>Medical marijuana and driving: A review</article-title>. <source>J Med Toxicol</source><volume>10</volume>: <fpage>269</fpage>&#8211;<lpage>279</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s13181-014-0393-4</pub-id><pub-id pub-id-type="pmid">24648180</pub-id><pub-id pub-id-type="pmcid">PMC4141931</pub-id></mixed-citation></ref><ref id="bibr46-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>AX</given-names></name><name name-style="western"><surname>Wu</surname><given-names>AY</given-names></name></person-group> (<year>2019</year>) <article-title>Association between cannabis and the eyelids: A comprehensive review</article-title>. <source>Clin Exp Ophthalmol</source><volume>48</volume>: <fpage>230</fpage>&#8211;<lpage>239</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/ceo.13687.</pub-id><pub-id pub-id-type="pmid">31747112</pub-id><pub-id pub-id-type="pmcid">PMC8328051</pub-id></mixed-citation></ref><ref id="bibr47-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niedbala</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kardos</surname><given-names>KW</given-names></name><name name-style="western"><surname>Fritch</surname><given-names>DF</given-names></name></person-group>, <etal>et al</etal>. (<year>2001</year>). <article-title>Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana</article-title>. <source>J Anal Toxicol</source><volume>25</volume>: <fpage>289</fpage>&#8211;<lpage>303</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/jat/25.5.289.</pub-id><pub-id pub-id-type="pmid">11499881</pub-id></mixed-citation></ref><ref id="bibr48-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papafotiou</surname><given-names>K</given-names></name><name name-style="western"><surname>Carter</surname><given-names>JD</given-names></name><name name-style="western"><surname>Stough</surname><given-names>C</given-names></name></person-group> (<year>2005</year>) <article-title>An evaluation of the sensitivity of the standardised field sobriety tests (SFSTs) to detect impairment due to marijuana intoxication</article-title>. <source>Psychopharmacology</source><volume>180</volume>: <fpage>107</fpage>&#8211;<lpage>114</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-004-2119-9</pub-id><pub-id pub-id-type="pmid">15619106</pub-id></mixed-citation></ref><ref id="bibr49-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>D</given-names></name><name name-style="western"><surname>Brophy</surname><given-names>H</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>IS</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Medicinal cannabis and driving: The intersection of health and road safety policy</article-title>. <source>Int J Drug Policy</source><volume>97</volume>: <fpage>103307</fpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103307</pub-id><pub-id pub-id-type="pmid">34107448</pub-id></mixed-citation></ref><ref id="bibr50-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ploner</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Tschirch</surname><given-names>A</given-names></name><name name-style="western"><surname>Ostendorf</surname><given-names>F</given-names></name></person-group> (<year>2002</year>) <article-title>Oculomotor effects of d-9-tetrahydrocannabinol in humans: Implications for the functional neuroanatomy of the brain cannabinoid system</article-title>. <source>Cereb Cortex</source><volume>12</volume>: <fpage>1016</fpage>&#8211;<lpage>1023</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/cercor/12.10.1016</pub-id><pub-id pub-id-type="pmid">12217964</pub-id></mixed-citation></ref><ref id="bibr51-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porath</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Beirness</surname><given-names>DJ</given-names></name></person-group> (<year>2019</year>) <article-title>Predicting categories of drugs used by suspected drug-impaired drivers using the drug evaluation and classification program tests</article-title>. <source>Traffic Inj Prev</source><volume>20</volume>: <fpage>255</fpage>&#8211;<lpage>263</lpage>. DOI: <pub-id pub-id-type="doi">10.1080/15389588.2018.1562178.</pub-id><pub-id pub-id-type="pmid">30946603</pub-id></mixed-citation></ref><ref id="bibr52-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porath-Waller</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Beirness</surname><given-names>DJ</given-names></name></person-group> (<year>2013</year>) <article-title>An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the drug evaluation and classification program</article-title>. <source>Traffic Inj Prev</source><volume>15</volume>: <fpage>125</fpage>&#8211;<lpage>131</lpage>. DOI: <pub-id pub-id-type="doi">10.1080/15389588.2013.800638.</pub-id><pub-id pub-id-type="pmid">24345013</pub-id></mixed-citation></ref><ref id="bibr53-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rafaelsen</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Bech</surname><given-names>P</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>1973</year>) <article-title>Cannabis and alcohol: Effects on simulated car driving</article-title>. <source>Science</source><volume>179</volume>: <fpage>920</fpage>&#8211;<lpage>923</lpage>. DOI: <pub-id pub-id-type="doi">10.1126/science.179.4076.920.</pub-id><pub-id pub-id-type="pmid">4569248</pub-id></mixed-citation></ref><ref id="bibr54-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaekers</surname><given-names>JG</given-names></name><name name-style="western"><surname>Mason</surname><given-names>NL</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>The why behind the high: Determinants of neurocognition during acute cannabis exposure</article-title>. <source>Nat Rev Neurosci</source><volume>22</volume>: <fpage>439</fpage>&#8211;<lpage>454</lpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41583-021-00466-4</pub-id><pub-id pub-id-type="pmid">34045693</pub-id></mixed-citation></ref><ref id="bibr55-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaekers</surname><given-names>JG</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>MR</given-names></name><name name-style="western"><surname>van Ruitenbeek</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>. (<year>2006</year>) <article-title>Cognition and motor control as a function of &#916;9-THC concentration in serum and oral fluid: Limits of impairment</article-title>. <source>Drug Alcohol Depend</source><volume>85</volume>: <fpage>114</fpage>&#8211;<lpage>122</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2006.03.015</pub-id><pub-id pub-id-type="pmid">16723194</pub-id></mixed-citation></ref><ref id="bibr56-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaekers</surname><given-names>JG</given-names></name><name name-style="western"><surname>Robbe</surname><given-names>HWJ</given-names></name><name name-style="western"><surname>O&#8217;Hanlon</surname><given-names>JF</given-names></name></person-group> (<year>2000</year>) <article-title>Marijuana, alcohol, and actual driving performance</article-title>. <source>Hum Psychopharmacol</source><volume>15</volume>: <fpage>551</fpage>&#8211;<lpage>558</lpage>. DOI: <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-1077(200010)15:7&amp;#x0003c;551::AID-HUP236&amp;#x0003e;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">12404625</pub-id></mixed-citation></ref><ref id="bibr57-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogeberg</surname><given-names>O</given-names></name><name name-style="western"><surname>Elvik</surname><given-names>R</given-names></name><name name-style="western"><surname>White</surname><given-names>M</given-names></name></person-group> (<year>2016</year>) <article-title>Correction to: &#8216;The effects of cannabis intoxication on motor vehicle collision revisited and revised&#8217;</article-title>. <source>Addiction</source><volume>113</volume>: <fpage>967</fpage>&#8211;<lpage>969</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/add.14140.</pub-id><pub-id pub-id-type="pmid">29359364</pub-id></mixed-citation></ref><ref id="bibr58-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ronen</surname><given-names>A</given-names></name><name name-style="western"><surname>Chassidim</surname><given-names>HS</given-names></name><name name-style="western"><surname>Gershon</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>. (<year>2010</year>). <article-title>The effect of alcohol, THC and their combination on perceived effects, willingness to drive, and performance of driving and non-driving tasks</article-title>. <source>Accid Anal Prev</source><volume>42</volume>: <fpage>1855</fpage>&#8211;<lpage>1865</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2010.05.006.</pub-id><pub-id pub-id-type="pmid">20728636</pub-id></mixed-citation></ref><ref id="bibr59-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ronen</surname><given-names>A</given-names></name><name name-style="western"><surname>Gershon</surname><given-names>P</given-names></name><name name-style="western"><surname>Drobiner</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. (<year>2008</year>) <article-title>Effects of THC on driving performance, physiological state, and subjective feelings relative to alcohol</article-title>. <source>Accid Anal Prev</source><volume>40</volume>: <fpage>926</fpage>&#8211;<lpage>934</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.aap.2007.10.011.</pub-id><pub-id pub-id-type="pmid">18460360</pub-id></mixed-citation></ref><ref id="bibr60-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruheel</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>Z</given-names></name><name name-style="western"><surname>Usman</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Facilitators and barriers to the regulation of medical cannabis: A scoping review of the peer-reviewed literature</article-title>. <source>Harm Reduct J</source><volume>18</volume>: <fpage>106</fpage>. DOI: <pub-id pub-id-type="doi">10.1186/s12954-021-00547-8</pub-id><pub-id pub-id-type="pmid">34649577</pub-id><pub-id pub-id-type="pmcid">PMC8515704</pub-id></mixed-citation></ref><ref id="bibr61-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagberg</surname><given-names>F</given-names></name><name name-style="western"><surname>Selpi</surname></name><name name-style="western"><surname>Piccinini</surname><given-names>GFB</given-names></name></person-group>, <etal>et al</etal>. (<year>2015</year>). <article-title>A review of research on driving styles and road safety. Human factors</article-title>. <source>J Hum Factors Ergon Soc</source><volume>57</volume>: <fpage>1248</fpage>&#8211;<lpage>1275</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0018720815591313</pub-id><pub-id pub-id-type="pmid">26130678</pub-id></mixed-citation></ref><ref id="bibr62-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahidi Zandi</surname><given-names>A</given-names></name><name name-style="western"><surname>Comeau</surname><given-names>FJE</given-names></name><name name-style="western"><surname>Mann</surname><given-names>RE</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Preliminary eye-tracking data as a non-intrusive marker for blood delta-9-tetrahydrocannabinol concentration and drugged driving</article-title>. <source>Cannabis Cannabinoid Res</source><volume>6</volume>: <fpage>537</fpage>&#8211;<lpage>547</lpage>. DOI: <pub-id pub-id-type="doi">10.1089/can.2020.0141</pub-id><pub-id pub-id-type="pmid">34432541</pub-id><pub-id pub-id-type="pmcid">PMC8713278</pub-id></mixed-citation></ref><ref id="bibr63-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiferaw</surname><given-names>BA</given-names></name><name name-style="western"><surname>Crewther</surname><given-names>DP</given-names></name><name name-style="western"><surname>Downey</surname><given-names>LA</given-names></name></person-group> (<year>2019</year>) <article-title>Gaze entropy measures detect alcohol induced driver impairment</article-title>. <source>Drug Alcohol Depend</source><volume>204</volume>: <fpage>107519</fpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.06.021.</pub-id><pub-id pub-id-type="pmid">31479863</pub-id></mixed-citation></ref><ref id="bibr64-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solowij</surname><given-names>N</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>RS</given-names></name><name name-style="western"><surname>Roffman</surname><given-names>RA</given-names></name></person-group>, <etal>et al</etal>. (<year>2002</year>) <article-title>Cognitive functioning of long-term heavy cannabis users seeking treatment</article-title>. <source>J Am Med Assoc</source><volume>287</volume>: <fpage>1123</fpage>&#8211;<lpage>1131</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.287.9.1123</pub-id><pub-id pub-id-type="pmid">11879109</pub-id></mixed-citation></ref><ref id="bibr65-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tement</surname><given-names>S</given-names></name><name name-style="western"><surname>Plohl</surname><given-names>N</given-names></name><name name-style="western"><surname>Horvat</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Driving demands, stress reactivity, and driving behaviour: An interactional approach</article-title>. <source>Traffic Psychol Behav</source><volume>69</volume>: <fpage>80</fpage>&#8211;<lpage>90</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.trf.2020.01.001</pub-id></mixed-citation></ref><ref id="bibr66-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandrey</surname><given-names>R</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>ES</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>JM</given-names></name></person-group>, <etal>et al</etal>. (<year>2017</year>) <article-title>Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes</article-title>. <source>J Anal Toxicol</source><volume>41</volume>: <fpage>83</fpage>&#8211;<lpage>99</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/jat/bkx012.</pub-id><pub-id pub-id-type="pmid">28158482</pub-id><pub-id pub-id-type="pmcid">PMC5890870</pub-id></mixed-citation></ref><ref id="bibr67-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veldstra</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bosker</surname><given-names>WM</given-names></name><name name-style="western"><surname>de Waard</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>. (<year>2015</year>) <article-title>Comparing treatment effects of oral THC on simulated and on-the-road driving performance: Testing the validity of driving simulator research</article-title>. <source>Psychopharmacology</source><volume>232</volume>: <fpage>2911</fpage>&#8211;<lpage>2919</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-015-3927-9.</pub-id><pub-id pub-id-type="pmid">25957748</pub-id><pub-id pub-id-type="pmcid">PMC4513227</pub-id></mixed-citation></ref><ref id="bibr68-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verster</surname><given-names>JC</given-names></name><name name-style="western"><surname>Roth</surname><given-names>T</given-names></name></person-group> (<year>2011</year>) <article-title>Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP)</article-title>. <source>Int J Gen Med</source><volume>4</volume>: <fpage>359</fpage>&#8211;<lpage>371</lpage>. DOI: <pub-id pub-id-type="doi">10.2147/IJGM.S19639.</pub-id><pub-id pub-id-type="pmid">21625472</pub-id><pub-id pub-id-type="pmcid">PMC3100218</pub-id></mixed-citation></ref><ref id="bibr69-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verster</surname><given-names>JC</given-names></name><name name-style="western"><surname>Roth</surname><given-names>T</given-names></name></person-group> (<year>2012</year>) <article-title>Drivers can poorly predict their own driving impairment: A comparison between measurements of subjective and objective driving quality</article-title>. <source>Psychopharmacology</source><volume>219</volume>: <fpage>775</fpage>&#8211;<lpage>781</lpage>. DOI: <pub-id pub-id-type="doi">10.1007/s00213-011-2400-7.</pub-id><pub-id pub-id-type="pmid">21750898</pub-id><pub-id pub-id-type="pmcid">PMC3259366</pub-id></mixed-citation></ref><ref id="bibr70-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu&#269;kovi&#263;</surname><given-names>S</given-names></name><name name-style="western"><surname>Srebro</surname><given-names>D</given-names></name><name name-style="western"><surname>Vujovi&#263;</surname><given-names>KS</given-names></name></person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Cannabinoids and pain: New insights from old molecules</article-title>. <source>Frontiers in Pharmacology</source><volume>9</volume>: <fpage>1259</fpage>. DOI: <pub-id pub-id-type="doi">10.3389/fphar.2018.01259.</pub-id><pub-id pub-id-type="pmid">30542280</pub-id><pub-id pub-id-type="pmcid">PMC6277878</pub-id></mixed-citation></ref><ref id="bibr71-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadsworth</surname><given-names>EJK</given-names></name><name name-style="western"><surname>Moss</surname><given-names>SC</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>SA</given-names></name></person-group>, <etal>et al</etal>. (<year>2006</year>) <article-title>Cannabis use, cognitive performance, and mood in a sample of workers</article-title>. <source>J Psychopharmacol</source><volume>20</volume>: <fpage>14</fpage>&#8211;<lpage>23</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881105056644</pub-id><pub-id pub-id-type="pmid">16204329</pub-id></mixed-citation></ref><ref id="bibr72-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whiting</surname><given-names>PF</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>RF</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2015</year>). <article-title>Cannabinoids for medical use: A systematic review and meta-analysis</article-title>. <source>JAMA</source><volume>313</volume>: <fpage>2456</fpage>&#8211;<lpage>2473</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.2015.6358.</pub-id><pub-id pub-id-type="pmid">26103030</pub-id></mixed-citation></ref><ref id="bibr73-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>JH</given-names></name><name name-style="western"><surname>San Miguel</surname><given-names>GG</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>JN</given-names></name></person-group>, <etal>et al</etal>. (<year>2019</year>). <article-title>Assessing attentional bias and inhibitory control in cannabis use disorder using an eye-tracking paradigm with personalized stimuli</article-title>. <source>Exp Clin Psychopharmacol</source><volume>27</volume>: <fpage>578</fpage>&#8211;<lpage>587</lpage>. DOI: <pub-id pub-id-type="doi">10.1037/pha0000274.</pub-id><pub-id pub-id-type="pmid">30907601</pub-id></mixed-citation></ref><ref id="bibr74-02698811231170360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuurman</surname><given-names>L</given-names></name><name name-style="western"><surname>Roy</surname><given-names>C</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>RC</given-names></name></person-group>, <etal>et al</etal>. (<year>2008</year>). <article-title>Effect of intrapulmonary tetrahydrocannabinol administration in humans</article-title>. <source>J Psychopharmacol</source><volume>22</volume>: <fpage>707</fpage>&#8211;<lpage>716</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0269881108089581.</pub-id><pub-id pub-id-type="pmid">18515447</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>